Literature DB >> 8598327

Preferential location of circulating activated cyclophosphamide within the erythrocyte.

M S Highley, P G Harper, P H Slee, E DeBruijn.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8598327     DOI： 10.1002/1097-0215(19960301)65:5<711::aid-ijc2910650503>3.0.co;2-h

Source DB:  PubMed          Journal:  Int J Cancer        ISSN： 0020-7136            Impact factor:   7.396


× No keyword cloud information.
  6 in total

Review 1.  Erythrocytes and the transport of drugs and endogenous compounds.

Authors:  M S Highley; E A De Bruijn
Journal:  Pharm Res       Date:  1996-02       Impact factor: 4.200

Review 2.  Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.

Authors:  T Kerbusch; J de Kraker; H J Keizer; J W van Putten; H J Groen; R L Jansen; J H Schellens; J H Beijnen
Journal:  Clin Pharmacokinet       Date:  2001-01       Impact factor: 6.447

3.  Oxazaphosphorine bioactivation and detoxification The role of xenobiotic receptors.

Authors:  Duan Wang; Hongbing Wang
Journal:  Acta Pharm Sin B       Date:  2012-04-01       Impact factor: 11.413

Review 4.  Clinical pharmacokinetics of cyclophosphamide.

Authors:  Milly E de Jonge; Alwin D R Huitema; Sjoerd Rodenhuis; Jos H Beijnen
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

5.  CITCO as an Adjuvant Facilitates CHOP-Based Lymphoma Treatment in hCAR-Transgenic Mice.

Authors:  Ritika Kurian; William Hedrich; Bryan Mackowiak; Linhao Li; Hongbing Wang
Journal:  Cells       Date:  2020-11-21       Impact factor: 6.600

6.  Genetic Polymorphism of GSTP-1 Affects Cyclophosphamide Treatment of Autoimmune Diseases.

Authors:  Péter Hajdinák; Melinda Szabó; Emese Kiss; Lili Veress; Lívius Wunderlich; András Szarka
Journal:  Molecules       Date:  2020-03-28       Impact factor: 4.411
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.